{
    "clinical_study": {
        "@rank": "120882", 
        "arm_group": [
            {
                "arm_group_label": "Probiotic Supplement", 
                "arm_group_type": "Experimental", 
                "description": "The probiotic supplement compound will consist of capsules containing approximately 10^8 colony forming units of the probiotic organisms, LactobacillusGG and Bifidobacteria lactis strain Bb12. The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. The participant will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks."
            }, 
            {
                "arm_group_label": "Inert Compound", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if taking a probiotic supplement versus a placebo\n      will lower rates of relapse and improve the clinical course among participants who have been\n      hospitalized for mania.  Relapse and clinical course are measured by time to\n      re-hospitalizations, new mood episodes, and changes in mood-related symptoms."
        }, 
        "brief_title": "Probiotics to Prevent Relapse After Hospitalization for Mania", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Bipolar Disorder", 
            "Schizoaffective Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bipolar Disorder", 
                "Psychotic Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18-65\n\n          -  Capacity for written informed consent\n\n          -  Currently admitted to a Sheppard Pratt inpatient or day hospital for symptoms of\n             mania\n\n          -  Primary Axis I diagnosis (DSM-IV) at time of admission of Bipolar I Disorder (single\n             manic episode, most recent episode manic, or most recent episode mixed) OR\n             Schizoaffective Disorder, Bipolar type (manic or mixed state)\n\n          -  Proficient in the English language\n\n          -  Available to come to Sheppard Pratt Towson for follow-up visits\n\n          -  Participated previously in one of our screening studies\n\n        Exclusion Criteria:\n\n          -  Diagnosis of mental retardation\n\n          -  Symptoms of mania secondary to a general medical condition\n\n          -  Any clinically significant or unstable medical disorder as determined by the\n             investigators including congestive heart failure, abnormal liver function or disease,\n             renal failure, acute pancreatitis, any diagnosis of cancer undergoing active\n             treatment, HIV infection or other immunodeficiency condition\n\n          -  History of IV drug use\n\n          -  Primary diagnosis of substance abuse or dependence according to DSM-IV criteria\n             within the last 3 months, or has a positive drug toxicity screen\n\n          -  Participated in any investigational drug trial in the past 30 days\n\n          -  Pregnant or planning to become pregnant during the study period\n\n          -  Receipt of antibiotic medication within the previous 24 hours (as anaerobic organisms\n             residing in the gastrointestinal tract may be minimally affected by antibiotics)\n\n          -  Documented celiac disease (as such persons should be on a gluten-free diet as this is\n             the standard care). Of note, we are not limiting the study to individuals with\n             elevated levels of gliadin or casein antibodies as we intend to look at these levels\n             as a predictor of response."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01731171", 
            "org_study_id": "SMRI/SPHS: 2012/1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Probiotic Supplement", 
                "description": "Probiotic Supplement 1 tablet by mouth daily", 
                "intervention_name": "Probiotic Supplement", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Probio-Tec"
            }, 
            {
                "arm_group_label": "Inert Compound", 
                "description": "Probiotic identical placebo 1 tablet by mouth daily", 
                "intervention_name": "Inert Compound", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "mania", 
            "manic episode", 
            "mixed episode", 
            "bipolar disorder", 
            "schizoaffective disorder", 
            "probiotics", 
            "probiotic supplement", 
            "relapse prevention", 
            "new mood episode", 
            "re-hospitalization"
        ], 
        "lastchanged_date": "August 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Batlimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21285"
                }, 
                "name": "Sheppard Pratt Health System"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blind Placebo-Controlled Trial of a Probiotic Supplement to Prevent Relapse and Improve the Clinical Course After Hospitalization for Mania", 
        "overall_official": {
            "affiliation": "Sheppard Pratt Health System", 
            "last_name": "Faith Dickerson, PhD, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "United States: Data and Safety Monitoring Board", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time to relapse is defined as time until re-hospitalization during the study period after a minimum of a 2 week interval after discharge from a previous hospital stay.", 
            "measure": "Time to relapse", 
            "safety_issue": "No", 
            "time_frame": "Weeks 1 - 24 of study participation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01731171"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sheppard Pratt Health System", 
            "investigator_full_name": "Faith Dickerson, PhD, MPH", 
            "investigator_title": "Head, Stanley Research Program", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "New mood episodes are defined by DSM-IV criteria for a manic, mixed, or depressive episode.", 
            "measure": "New mood episode", 
            "safety_issue": "No", 
            "time_frame": "Weeks 1 - 24 of study participation"
        }, 
        "source": "Sheppard Pratt Health System", 
        "sponsors": {
            "collaborator": {
                "agency": "Stanley Medical Research Institute", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Sheppard Pratt Health System", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}